Geron Corporation (GERN)

Geron is a late-stage commercial biotech riding the launch of imetelstat (Rytelo), its first-ever approved therapy for lower-risk myelodysplastic syndromes (MDS), which drove 30.9% revenue growth and a perfect 4-of-4 EPS beat streak in early commercialization. The analyst community leans bullish with a consensus price target of $3.40 — more than double the current price — reflecting confidence in Rytelo's addressable market and differentiated mechanism. The primary risk remains a prolonged path to profitability, with the stock still loss-making and dependent on continued Rytelo uptake to fund operations.

• Rytelo (imetelstat) quarterly sales updates — continued revenue acceleration in MDS could serve as a key re-rating event, with next earnings report expected to show whether the 30.9% growth trajectory is sustained or improving.
• Potential label expansion into higher-risk MDS or other hematologic malignancies, which would materially broaden the addressable patient population and support a significant upward revision to consensus revenue estimates.
• Analyst coverage expansion and institutional accumulation — as Rytelo gains commercial traction and revenue visibility improves, additional sell-side initiations could further validate the bull thesis and compress the current discount to the $3.40 consensus target.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →